期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 38, 期 1, 页码 92-99出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2016.10.006
关键词
-
资金
- Swedish Cancer Society
- Cancer Prevention and Research Institute of Texas [RP110444-P1]
- Robert A. Welch Foundation [E-0004]
- CIMED
A major issue in clinical endocrinology today is how to use hormones to achieve the health benefits that they clearly can provide but avoid the negative side effects, that is, how to develop more precise medicines. This problem of how to use hormones is pervasive in clinical endocrinology. It is true for estrogen, progesterone, androgen, vitamin D, and thyroid hormone, and the problem is amplified in the case of new ligands for the more recently discovered nuclear receptors. Selective targeting of hormone receptor subtypes is one attractive way to harness the beneficial effects of hormones while reducing unwanted side effects. Here, we focus on estrogen receptor (ER)beta, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据